

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|----|--|
| (51) International Patent Classification ⁶ : C12N 15/57, 15/63, 9/54, 1/21 | A3 | (11) International Publication Number: WO 99/53038 (43) International Publication Date: 21 October 1999 (21.10.99) |
| (21) International Application Number: PCT/US99/08253 | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). |
| (22) International Filing Date: 14 April 1999 (14.04.99) | | |
| (30) Priority Data: 09/060,872 15 April 1998 (15.04.98) US | | |
| (71) Applicant: GENENCOR INTERNATIONAL, INC. [US/US]; 4 Cambridge Place, 1870 South Winton Road, Rochester, NY 14618 (US). | | |
| (72) Inventors: ESTELL, David, A.; 248 Woodbridge Circle, San Mateo, CA 94403 (US). HARDING, Fiona, A.; 772 Lewis Street, Santa Clara, CA 95050 (US). | | Published <i>With international search report</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (74) Agent: STONE, Christopher, L.; Genencor International, Inc., 925 Page Mill Road, Palo Alto, CA 94304-1013 (US). | | (88) Date of publication of the international search report: 10 February 2000 (10.02.00) |

(54) Title: MUTANT PROTEINS HAVING LOWER ALLERGENIC RESPONSE IN HUMANS AND METHODS FOR CONSTRUCTING, IDENTIFYING AND PRODUCING SUCH PROTEINS

(57) Abstract

The present invention relates to a novel improved protein mutant which produces low allergenic response in humans compared to the parent of that mutant. Specifically, the present invention comprises neutralizing or reducing the ability of T-cells to recognize epitopes and thus prevent sensitization of an individual to the protein.

Entered into Database

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

INTERNATIONAL SEARCH REPORT

| |
|------------------------------|
| International Application No |
| PCT/US 99/08253 |

| | | | |
|---|---|--|--|
| A. CLASSIFICATION OF SUBJECT MATTER | | | |
| IPC 6 C12N15/57 C12N15/63 C12N9/54 C12N1/21 | | | |
| According to International Patent Classification (IPC) or to both national classification and IPC | | | |
| B. FIELDS SEARCHED | | | |
| Minimum documentation searched (classification system followed by classification symbols) | | | |
| IPC 6 C12N | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | | |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used) | | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
| Category ³ | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | |
| P, X | WO 98 20116 A (NOVONORDISK AS) 14 May 1998 (1998-05-14) * see claims 13-17* the whole document --- | 1-8 | |
| X | WO 96 34946 A (NOVONORDISK AS) 7 November 1996 (1996-11-07) * see claims 13-15 * the whole document --- | 1-11 | |
| Y | WO 92 10755 A (NOVONORDISK AS) 25 June 1992 (1992-06-25) | 1-11 | |
| X | the whole document --- | 13, 14 | |
| Y | EP 0 006 638 A (NOVO INDUSTRI AS) 9 January 1980 (1980-01-09) the whole document --- | 1-11 | |
| | | - / -- | |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. | | <input checked="" type="checkbox"/> Patent family members are listed in annex. | |
| * Special categories of cited documents : | | | |
| *A* document defining the general state of the art which is not considered to be of particular relevance | | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention | |
| *E* earlier document but published on or after the international filing date | | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | |
| *O* document referring to an oral disclosure, use, exhibition or other means | | *Z* document member of the same patent family | |
| *P* document published prior to the international filing date but later than the priority date claimed | | | |
| Date of the actual completion of the international search | | Date of mailing of the international search report | |
| 30 November 1999 | | 10. 12. 99 | |
| Name and mailing address of the ISA European Patent Office, P. B. 5818 Patentlaan 2 | | Authorized officer | |

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/08253

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| A | GUNDLACH B R ET AL: "Determination of T cell epitopes with random peptide libraries" JOURNAL OF IMMUNOLOGICAL METHODS, NL, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, vol. 192, no. 1, page 149-155 XP004020829 ISSN: 0022-1759 abstract --- | 12 |
| Y | WO 97 30148 A (NOVONORDISK AS ;PRENTOE ANNETTE (DK); BISGAARD FRANTZEN HENRIK (DK) 21 August 1997 (1997-08-21) the whole document --- | 13 |
| Y | WO 96 16177 A (NOVONORDISK AS ;BJOERNVAD MADS ESKELUND (DK); PRENTOE ANNETTE (DK)) 30 May 1996 (1996-05-30) the whole document ----- | 13 |

INTERNATIONAL SEARCH REPORT

International application No
PCT/US 99/08253

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 15-16 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
The subject-matter of claims 15-16 is so broadly and imprecisely drafted with respect to the claimed proteins that no meaningful search could be carried out.

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos. .

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos. .

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 99/08253

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 15-16

The subject-matter of claims 15-16 is so broadly and imprecisely drafted with respect to the claimed proteins that no meaningful search could be carried out.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99/08253

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11

The subject-matter of claims 1-11 is directed to specific protease (subtilisin) variants, a DNA encoding said variants, an expression vector encoding said DNA, and a cleaning composition or animal feed comprising said protease (subtilisin) variants.

2. Claim : 12

The subject-matter of claim 12 is directed to a method for determining T-cell epitopes in humans.

3. Claims: 13-14

The subject-matter of claims 13-14 is directed to a method of reducing the allergenicity of a protein.

The subject-matter of the present set of claims is not so linked together by a specific technical feature as to form a single general inventive concept.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/08253

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|--|--|
| WO 9820116 | A 14-05-1998 | AU 4773197 A EP 0932667 A | 29-05-1998 04-08-1999 |
| WO 9634946 | A 07-11-1996 | AU 5644896 A BR 9608149 A CA 2219949 A CN 1183800 A EP 0824585 A JP 11504805 T US 5837517 A | 21-11-1996 09-02-1999 07-11-1996 03-06-1998 25-02-1998 11-05-1999 17-11-1998 |
| WO 9210755 | A 25-06-1992 | AT 170630 T AU 9052891 A CA 2095852 A DE 69130113 D DE 69130113 T EP 0561907 A FI 932561 A JP 6502994 T US 5766898 A | 15-09-1998 08-07-1992 06-06-1992 08-10-1998 12-05-1999 29-09-1993 04-06-1993 07-04-1994 16-06-1998 |
| EP 0006638 | A 09-01-1980 | BE 877435 A BR 7904209 A CA 1142105 A CH 642395 A DE 2926808 A DK 281579 A,B, ES 482133 A FR 2430453 A GB 2024830 A,B IT 1162338 B JP 1241461 C JP 55039794 A JP 59013187 B MX 6034 E NL 7905172 A SE 447661 B SE 7905828 A US 4266031 A YU 161379 A | 03-01-1980 17-06-1980 01-03-1983 13-04-1984 17-01-1980 05-01-1980 01-04-1980 01-02-1980 16-01-1980 25-03-1987 26-11-1984 19-03-1980 28-03-1984 04-10-1984 08-01-1980 01-12-1986 05-01-1980 05-05-1981 30-04-1984 |
| WO 9730148 | A 21-08-1997 | AU 1540697 A CA 2242488 A CN 1211278 A EP 0894128 A | 02-09-1997 21-08-1997 17-03-1999 03-02-1999 |
| WO 9616177 | A 30-05-1996 | AU 3924095 A EP 0793726 A JP 10509324 T | 17-06-1996 10-09-1997 14-09-1998 |

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



1/1
COP

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


| | | | |
|--|--|---|--|
| <p>(51) International Patent Classification ⁶ : C12N 15/57, 9/64, 9/54, 1/21, A61K 38/48</p> | | <p>A2</p> | <p>(11) International Publication Number: WO 99/53078 (43) International Publication Date: 21 October 1999 (21.10.99)</p> |
| <p>(21) International Application Number: PCT/US99/08177</p> | | <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> | |
| <p>(22) International Filing Date: 15 April 1999 (15.04.99)</p> | | <p>(30) Priority Data: 09/060,854 15 April 1998 (15.04.98) US</p> | |
| <p>(71) Applicant: GENENCOR INTERNATIONAL, INC. [US/US]; 4 Cambridge Place, 1870 South Winton Road, Rochester, NY 14618 (US).</p> | | <p>(72) Inventor: ESTELL, David; 248 Woodbridge Circle, San Mateo, CA 94403 (US).</p> | |
| <p>(74) Agent: STONE, Christopher, L.; Genencor International, Inc., 925 Page Mill Road, Palo Alto, CA 94304-1013 (US).</p> | | <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p> | |
| <p>(54) Title: HUMAN PROTEASE AND USE OF SUCH PROTEASE FOR PHARMACEUTICAL APPLICATIONS AND FOR REDUCING THE ALLERGENICITY OF NON-HUMAN PROTEINS</p> | | | |
| <p>(57) Abstract</p> <p>The present invention relates to a method of producing novel improved protein mutant which produce low allergenic response in humans compared to the parent of that mutant. Specifically, the present invention comprises neutralizing or reducing the allergenicity of a protein by introducing therein as replacement or modification of an epitope on such protein a sequence from human subtilisin.</p> <p><i>not available for review P-5</i></p> | | | |



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | | | PT | Portugal | | |
| CN | China | KR | Republic of Korea | RO | Romania | | |
| CU | Cuba | KZ | Kazakhstan | RU | Russian Federation | | |
| CZ | Czech Republic | LC | Saint Lucia | SD | Sudan | | |
| DE | Germany | LJ | Liechtenstein | SE | Sweden | | |
| DK | Denmark | LK | Sri Lanka | SG | Singapore | | |
| EE | Estonia | LR | Liberia | | | | |



HUMAN PROTEASE AND USE OF SUCH PROTEASE FOR PHARMACEUTICAL APPLICATIONS AND FOR REDUCING THE ALLERGENICITY OF NON-HUMAN PROTEINS

A. Field of the Invention


Role of the Innovation

The present invention relates to a human protein sequence which can be used in several applications. Specifically, the novel human protein sequence can be used to design proteins which produce lower allergenic response in humans exposed to such proteins through the use of a predictive assay.

B. State of the Art

15 Serine proteases are a subgroup of carbonyl hydrolases. They comprise a diverse class of enzymes having a wide range of specificities and biological functions. Stroud, R. Sci. Amer., **131**:74-88. Despite their functional diversity, the catalytic machinery of serine proteases has been approached by at least two genetically distinct families of enzymes: the subtilisins and the mammalian chymotrypsin related and homologous bacterial serine 20 proteases (e.g., trypsin and *S. gresius* trypsin). These two families of serine proteases show remarkably similar mechanisms of catalysis. Kraut, J. (1977), Ann. Rev. Biochem., **46**:331-358. Furthermore, although the primary structure is unrelated, the tertiary structure of these two enzyme families bring together a conserved catalytic triad of amino acids consisting of serine, histidine and aspartate.

25 Subtilisin is a serine endoprotease (MW 27,500) which is secreted in large amounts from a wide variety of *Bacillus* species and other microorganisms. The protein sequence of subtilisin has been determined from at least four different species of *Bacillus*. Markland, F.S., et al. (1983), Honne-Seyler's Z. Physiol. Chem., **364**:1537-1540. The three-dimensional crystallographic structure of *Bacillus amyloliquefaciens* subtilisin to 2.5A resolution has also been reported. Wright, C.S., et al. (1969), Nature, **221**:235-242; Drenth, J., et al. (1972), Eur. J. Biochem., **26**:177-181. These studies indicate that although subtilisin is genetically unrelated to the mammalian chymotrypsin like serine proteases, it has a similar active site structure. The x-ray crystal structures of subtilisin containing covalently bound peptide inhibitors (Robertus, J.D., et al. (1972), Biochemistry, **11**:2439-2449) or product complexes (Robertus, J.D., et al. (1976), J. Biol. Chem., **251**:1097-1103) have also provided information regarding the active site and putative substrate binding cleft of subtilisin. In addition, a large number of kinetic and chemical




modification studies have been reported for subtilisin (Philipp, M., et al. (1983), Mol. Cell. Biochem., **51**:5-32; Svendsen, B. (1976), Carlsberg Res. Comm., **41**:237-291; Markland, F.S. Id.) as well as at least one report wherein the side chain of methionine at residue 222 of subtilisin was converted by hydrogen peroxide to methionine-sulfoxide (Stauffer, D.C., et al. (1965), J. Biol. Chem., **244**:5333-5338) and the side chain of serine at residue 221 converted to cysteine by chemical modification (Polgar, et al. (1981), Biochimica et Biophysica Acta, **667**:351-354.)

Proteins bearing some resemblance and/or homology to bacterial subtilisin have also been detected in humans as well (see e.g., Keifer et al., DNA and Cell Biol., Vol. 10, No. 10, pp. 757-769 (1991); Smeekens et al., J. Biol. Chem., Vol. 265, No. 6, pp. 2997-3000 (1990); Tomkinson et al., Biochem., Vol. 30, pp. 168-174 (1991)).

US Patent 4,760,025 (RE 34,606) discloses the modification of subtilisin amino acid residues corresponding to positions in *Bacillus amyloliquefaciens* subtilisin tyrosine -1, aspartate +32, asparagine +155, tyrosine +104, methionine +222, glycine +166, histidine +64, glycine +169, phenylalanine +189, serine +33, serine +221, tyrosine +217, glutamate +156 and alanine +152. US Patent 5,182,204 discloses the modification of the amino acid +224 residue in *Bacillus amyloliquefaciens* subtilisin and equivalent positions in other subtilisins which may be modified by way of substitution, insertion or deletion and which may be combined with modifications to the residues identified in US Patent 4,760,025 (RE 34,606) to form useful subtilisin mutants or variants. US Patent 5,155,033 discloses similar mutant subtilisins having a modification at an equivalent position to +225 of *B. amyloliquefaciens* subtilisin. US Patents 5,185,258 and 5,204,015 disclose mutant subtilisins having a modification at positions +123 and/or +274. US Patent 5,182,204 discloses the modification of many amino acid residues within subtilisin, including specifically +99, +101, +103, +107, +126, +128, +135, +197 and +204. US Patent 4,914,031 discloses certain subtilisin analogs, including a subtilisin modified at position +76.

Proteins, including proteases, used in industrial, pharmaceutical and commercial applications are of increasing prevalence. As a result, the increased exposure due to this prevalence has been responsible for some safety hazards caused by the sensitization of certain persons to those peptides, whereupon subsequent exposure causes extreme allergic reactions which can be injurious and even fatal. For example, proteases are known to cause dangerous hypersensitivity in some individuals. As a result, despite the usefulness of proteases in industry, e.g., in laundry detergents, cosmetics, textile treatment etc...., and the extensive research performed in the field to provide improved




proteases which have, for example, more effective stain removal under detergency conditions, the use of proteases in industry has been problematic due to their ability to produce a hypersensitive allergic response in some humans.

Much work has been done to alleviate these problems. Among the strategies 5 explored to reduce immunogenic potential of protease use have been improved production processes which reduce potential contact by controlling and minimizing workplace concentrations of dust particles or aerosol carrying airborne protease, improved granulation processes which reduce the amount of dust or aerosol actually produced from the protease product, and improved recovery processes to reduce the level of potentially 10 allergenic contaminants in the final product. However, efforts to reduce the allergenicity of protease, *per se*, have been relatively unsuccessful. Alternatively, efforts have been made to mask epitopes in protease which are recognized by immunoglobulin E (IgE) in hypersensitive individuals (PCT Publication No. WO 92/10755) or to enlarge or change the 15 nature of the antigenic determinants by attaching polymers or peptides/proteins to the problematic protease.

When an adaptive immune response occurs in an exaggerated or inappropriate form, the individual experiencing the reaction is said to be hypersensitive. Hypersensitivity reactions are the result of normally beneficial immune responses acting inappropriately and sometimes cause inflammatory reactions and tissue damage. They can be provoked 20 by many antigens; and the cause of a hypersensitivity reaction will vary from one individual to the next. Hypersensitivity does not normally manifest itself upon first contact with the antigen, but usually appears upon subsequent contact. One form of hypersensitivity occurs when an IgE response is directed against innocuous environmental 25 antigens, such as pollen, dust-mites or animal dander. The resulting release of pharmacological mediators by IgE-sensitized mast cells produces an acute inflammatory reaction with symptoms such as asthma or rhinitis.

Nonetheless, a strategy comprising modifying the IgE sites will not generally be 30 successful in preventing the cause of the initial sensitization reaction. Accordingly, such strategies, while perhaps neutralizing or reducing the severity of the subsequent hypersensitivity reaction, will not reduce the number or persons actually sensitized. For example, when a person is known to be hypersensitive to a certain antigen, the general, and only safe, manner of dealing with such a situation is to isolate the hypersensitive 35 person from the antigen as completely as possible. Indeed, any other course of action would be dangerous to the health of the hypersensitive individual. Thus, while reducing



the danger of a specific protein for a hypersensitive individual is important, for industrial purposes it would be far more valuable to render a protein incapable of initiating the hypersensitivity reaction in the first place.

5 T-lymphocytes (T-cells) are key players in the induction and regulation of immune responses and in the execution of immunological effector functions. Specific immunity against infectious agents and tumors is known to be dependent on these cells and they are believed to contribute to the healing of injuries. On the other hand, failure to control these responses can lead to auto aggression. In general, antigen is presented to T-cells

10 in the form of antigen presenting cells which, through a variety of cell surface mechanisms, capture and display antigen or partial antigen in a manner suitable for antigen recognition by the T-cell. Upon recognition of a specific epitope by the receptors on the surface of the T-cells (T-cell receptors), the T-cells begin a series of complex interactions, including proliferation, which result in the production of antibody by B-cells.

15 While T-cells and B-cells are both activated by antigenic epitopes which exist on a given protein or peptide, the actual epitopes recognized by these mononuclear cells are generally not identical. In fact, the epitope which activates a T-cell to initiate the creation of immunologic diversity is quite often not the same epitope which is later recognized by B-cells in the course of the immunologic response. Thus, with respect to hypersensitivity,


20 while the specific antigenic interaction between the T-cell and the antigen is a critical element in the initiation of the immune response to antigenic exposure, the specifics of that interaction, i.e., the epitope recognized, is often not relevant to subsequent development of a full blown allergic reaction.

25 PCT Publication No. WO 96/40791 discloses a process for producing polyalkylene oxide-polypeptide conjugates with reduced allergenicity using polyalkylene oxide as a starting material.

PCT Publication No. WO 97/30148 discloses a polypeptide conjugate with reduced allergenicity which comprises one polymeric carrier molecule having two or more polypeptide molecules coupled covalently thereto.

30 PCT Publication No. WO 96/17929 discloses a process for producing polypeptides with reduced allergenicity comprising the step of conjugating from 1 to 30 polymolecules to a parent polypeptide.

35 PCT Publication No. WO 92/10755 discloses a method of producing protein variants evoking a reduced immunogenic response in animals. In this application, the proteins of interest, a series of proteases and variants thereof, were used to immunized



rats. The sera from the rats was then used to measure the reactivity of the polyclonal antibodies already produced and present in the immunized sera to the protein of interest and variants thereof. From these results, it was possible to determine whether the antibodies in the preparation were comparatively more or less reactive with the protein and its variants, thus permitting an analysis of which changes in the protein are likely to neutralize or reduce the ability of the Ig to bind. From these tests on rats, the conclusion was arrived at that changing any of subtilisin 309 residues corresponding to 127, 128, 129, 130, 131, 151, 136, 151, 152, 153, 154, 161, 162, 163, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 186, 193, 194, 195, 196, 197, 247, 251, 261 will result in a change in the immunological potential.

PCT Publication No. WO 94/10191 discloses low allergenic proteins comprising oligomeric forms of the parent monomeric protein, wherein the oligomer has substantially retained its activity.

The prior art has provided methods of reducing the allergenicity of certain proteins and identification of epitopes which cause allergic reactions in some individuals, the assays used to identify these epitopes generally involving measurement of IgE and IgG antibody in blood sera previously exposed to the antigen. Nonetheless, a need continues for alternate methods of preparing low allergenicity enzymes. Likewise, a need exists for an increased availability of human enzymes which may have use in pharmaceutical applications.


SUMMARY OF THE INVENTION

It is an object of the invention to provide a human protease which can be used in industry as a replacement for bacterial and fungal proteases.

It is an object of the invention to provide a method of making currently used and successful proteases and other proteins more safe by integrating therein sequences derived from human protease analogs.

It is a further object of the invention to provide a human protease which may have application in the pharmaceutical industry.

According to the present invention, a method for reducing the allergenicity of a non-human protein is provided wherein an epitope is identified and replaced with an analogous region within a human subtilisin. In a preferred embodiment the non-human protein is an enzyme, more preferably a protease. In another preferred embodiment, the epitope replaced is a T-cell epitope.



In another embodiment of the present invention, a method for producing the protein of the invention having reduced allergenicity is provided. Preferably, the mutant protein is prepared by modifying a DNA encoding a precursor protein so that the modified DNA encodes the mutant protein of the invention wherein an epitope is replaced with an 5 analogous region from human subtilisin.

In yet another embodiment of the invention, DNA sequences encoding the mutant protein, as well as expression vectors containing such DNA sequences and host cells transformed with such vectors are provided, which host cells are preferably capable of expressing such DNA to produce the mutant protein of the invention either intracellularly 10 or extracellularly.

The mutant protein of the invention is useful in any composition or process in which the protein is generally known to be useful. For example, where the protein is a protease, the reduced allergenicity protease can be used as a component in cleaning products such as laundry detergents and hard surface cleansers, as an aid in the 15 preparation of leather, in the treatment of textiles such as wool and/or silk to reduce felting, as a component in a cosmetic or face cream, and as a component in animal or pet feed to improve the nutritional value of the feed. Similarly, where the protein is an amylase, the reduced allergenicity amylase can be used for the liquefaction of starch, as a component in a dishwashing detergent, for desizing of textiles, in a laundry detergent or 20 any other use for which amylase is useful. Similarly, where the protein is a pharmaceutical composition, its use can be made more safe by reducing the possibility of allergic reaction.

In another embodiment of the invention, the human subtilisin may be used in pharmaceutical applications wherein the protease is used for debridement treatments.

25

BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1 A-C illustrates the DNA (SEQ ID:NO 1) and amino acid (SEQ ID:NO 2) sequence for *Bacillus amyloliquefaciens* subtilisin (BPN') and a partial restriction map of this gene.

30 Fig. 2 illustrates the conserved amino acid residues among subtilisins from *Bacillus amyloliquefaciens* and *Bacillus lentinus* (wild-type)(SEQ ID:NO 3).

35 Figs. 3A and 3B illustrate an amino acid sequence alignment of subtilisin type proteases from *Bacillus amyloliquefaciens* (BPN'), *Bacillus subtilis*, *Bacillus licheniformis* (SEQ ID:NO 4) and *Bacillus lentinus*. The symbol * denotes the absence of specific amino acid residues as compared to subtilisin BPN'.




Fig. 4. illustrates the additive T-cell response of 16 peripheral mononuclear blood samples to peptides corresponding to the *Bacillus lentinus* protease. Peptide E05 represents the region comprising residues corresponding to 170-173 in protease from *Bacillus amyloliquefaciens*.

5 Fig. 5 illustrate the additive T-cell response of 10 peripheral mononuclear blood sample to peptides corresponding to the human subtilisin.

Fig. 6 illustrates the amino acid sequence of human subtilisin (SEQ ID: NO 6).

Fig. 7 illustrates the amino acid strings corresponding to peptides derived from the sequence of *Bacillus lentinus* protease used in Example 2.

10 Figs. 8A and 8B illustrate the amino acid strings corresponding to peptides derived from the sequence of human subtilisin used in Example 2.


DETAILED DESCRIPTION OF THE INVENTION

According to the present invention, a method for reducing the allergenicity of a 15 non-human protein is provided wherein an epitope is identified and replaced with an analogous region within a human subtilisin. In a preferred embodiment the non-human protein is an enzyme, more preferably a protease. In another preferred embodiment, the epitope replaced is a T-cell epitope.

In another embodiment of the present invention, a method for producing the 20 protein of the invention having reduced allergenicity is provided. Preferably, the mutant protein is prepared by modifying a DNA encoding a precursor protein so that the modified DNA encodes the mutant protein of the invention wherein an epitope is replaced with an analogous region from human subtilisin.

In yet another embodiment of the invention, DNA sequences encoding the mutant 25 protein, as well as expression vectors containing such DNA sequences and host cells transformed with such vectors are provided, which host cells are preferably capable of expressing such DNA to produce the mutant protein of the invention either intracellularly or extracellularly.


According to a preferred embodiment of the present invention, the epitope to be 30 replaced in the non-human protein of interest is identified by a method for identifying T-cell epitopes. In a preferred embodiment of the invention, the present invention provides an assay which identifies epitopes as follows: differentiated dendritic cells are combined with naïve human CD4+ and/or CD8+ T-cells and with a peptide of interest. More specifically, a method is provided wherein a T-cell epitope is recognized comprising the steps of: (a) 35 obtaining from a single blood source a solution of dendritic cells and a solution of naïve



CD4+ and/or CD8+ T-cells; (b) promoting differentiation in said solution of dendritic cells; (c) combining said solution of differentiated dendritic cells and said naïve CD4+ and/or CD8+ T-cells with a peptide of interest; (d) measuring the proliferation of T-cells in said step (c).

5 The non-human peptide of interest to be analyzed according to the assay of the invention is derived from a protein or enzyme for which reduced allergenicity is required. In the practice of the invention, it is possible to identify with precision the location of an epitope which can cause sensitization in an individual or sampling of individuals. In a particularly effective embodiment of the invention, a series of peptide oligomers which
10 correspond to all or part of the protein or enzyme are prepared. For example, a peptide library is produced covering the relevant portion or all of the protein. One particularly useful manner of producing the peptides is to introduce overlap into the peptide library, for example, producing a first peptide corresponds to amino acid sequence 1-10 of the subject protein, a second peptide corresponds to amino acid sequence 4-14 of the subject protein,
15 a third peptide corresponds to amino acid sequence 7-17 of the subject protein, a fourth peptide corresponds to amino acid sequence 10-20 of the subject protein etc. . . until representative peptides corresponding to the entire molecule are created. By analyzing each of the peptides individually in the assay provided herein, it is possible to precisely identify the location of epitopes recognized by T-cells. In the example above, the
20 reaction of one specific peptide to a greater extent than it's neighbors will facilitate identification of the epitope anchor region to within three amino acids. After determining the location of these epitopes, it is possible to alter the amino acids within each epitope until the peptide produces a less significant T-cell response.

25 Preferably, the epitope is modified in one of the following ways: (a) preferably the amino acid sequence of the epitope is substituted with an analogous sequence from the human subtilisin of the invention to the protein of interest, e.g., where the protein is a subtilisin, a sequence alignment can be arranged so as to find the analogous region in the human subtilisin molecule with which to replace the pertinent epitope in the subtilisin; (b) the amino acid sequence of the epitope is substituted with a sequence from human
30 subtilisin of the invention which substantially mimics the major tertiary structure attributes of the epitope, but which produces a lesser allergenic response due to T-cell epitope recognition than that of the protein of interest; or (c) with any sequence from the human subtilisin of the invention which produces lesser allergenic response due to T-cell epitope recognition than that of the protein of interest.



"Antigen presenting cell" as used herein means a cell of the immune system which present antigen on their surface which is recognizable by T-cells. Examples of antigen presenting cells are dendritic cells, interdigitating cells, activated B-cells and macrophages.

5 "T-cell proliferation" as used herein means the number of T-cells produced during the incubation of T-cells with the antigen presenting cells, with or without antigen.


"Baseline T-cell proliferation" as used herein means T-cell proliferation which is normally seen in an individual in response to exposure to antigen presenting cells in the absence of peptide or protein antigen. For the purposes herein, the baseline T-cell 10 proliferation level was determined on a per sample basis for each individual as the proliferation of T-cells in response to antigen presenting cells in the absence of antigen.

"T-cell epitope" means a feature of a peptide or protein which is recognized by a T-cell receptor in the initiation of an immunologic response to the peptide comprising that antigen. Recognition of a T-cell epitope by a T-cell is generally believed to be via a 15 mechanism wherein T-cells recognize peptide fragments of antigens which are bound to class I or class II major histocompatibility (MHC) molecules expressed on antigen-presenting cells (see e.g., Moeller, G. ed., Antigenic Requirements for Activation of MHC-Restricted Responses, Immunological Review, Volume 98, p 187 (Copenhagen; Munksgaard) (1987)).

20 The epitopes determined according to the assay provided herein are then modified to reduce the allergenic potential of the protein of interest. In a preferred embodiment, the epitope to be modified produces a level of T-cell proliferation of greater than three times the baseline T-cell proliferation in a sample. When modified, the epitope produces less than three times the baseline proliferation, preferably less than two times the baseline 25 proliferation and most preferably less than or substantially equal to the baseline proliferation in a sample.

"Sample" as used herein comprises mononuclear cells which are naïve, i.e., not sensitized, to the antigen in question.

30 "Homolog" as used herein means a protein or enzyme which has similar catalytic action, structure and/or use as the protein of interest. It is desirable to find a homolog that has a tertiary and/or primary structure similar to the protein of interest as replacement of the epitope in the protein of interest with an analogous segment from the homolog will reduce the disruptiveness of the change. Thus, enzymes having significant homology will provide the most desirable target for epitope substitutions with sequences from the human 35 subtilisin of the invention.




An "analogous" sequence may be determined by ensuring that the replacement amino acids show a similar function, the tertiary structure and/or conserved residues to the amino acids in the protein of interest at or near the epitope. Thus, where the epitope region contains, for example, an alpha-helix or a beta-sheet structure, the replacement 5 amino acids should maintain that specific structure.

While the present invention extends to all proteins for which it is desired to reduce allergenicity, for the sake of simplicity, the following will describe a particularly preferred embodiment of the invention, the modification of protease. Proteases are carbonyl 10 hydrolases which generally act to cleave peptide bonds of proteins or peptides. As used herein, "protease" means a naturally-occurring protease or a recombinant protease. Naturally-occurring proteases include α -aminoacylpeptide hydrolase, peptidylamino acid hydrolase, acylamino hydrolase, serine carboxypeptidase, metallocarboxypeptidase, thiol 15 proteinase, carboxylproteinase and metalloproteinase. Serine, metallo, thiol and acid proteases are included, as well as endo and exo-proteases.

Subtilisins are bacterial or fungal proteases which generally act to cleave peptide bonds of proteins or peptides. As used herein, "subtilisin" means a naturally-occurring subtilisin or a recombinant subtilisin. A series of naturally-occurring subtilisins is known to be produced and often secreted by various microbial species. Amino acid sequences of 20 the members of this series are not entirely homologous. However, the subtilisins in this series exhibit the same or similar type of proteolytic activity. This class of serine proteases shares a common amino acid sequence defining a catalytic triad which distinguishes them from the chymotrypsin related class of serine proteases. The subtilisins and chymotrypsin related serine proteases both have a catalytic triad 25 comprising aspartate, histidine and serine. In the subtilisin related proteases the relative order of these amino acids, reading from the amino to carboxy terminus, is aspartate-histidine-serine. In the chymotrypsin related proteases, the relative order, however, is histidine-aspartate-serine. Thus, subtilisin herein refers to a serine protease having the catalytic triad of subtilisin related proteases. Examples include but are not limited to the 30 subtilisins identified in Fig. 3 herein. Generally and for purposes of the present invention, numbering of the amino acids in proteases corresponds to the numbers assigned to the mature *Bacillus amyloliquefaciens* subtilisin sequence presented in Fig. 1.

"Recombinant subtilisin" or "recombinant protease" refer to a subtilisin or protease 35 in which the DNA sequence encoding the subtilisin or protease is modified to produce a variant (or mutant) DNA sequence which encodes the substitution, deletion or insertion of



one or more amino acids in the naturally-occurring amino acid sequence. Suitable methods to produce such modification, and which may be combined with those disclosed herein, include those disclosed in US Patent 4,760,025 (RE 34,606), US Patent 5,204,015 and US Patent 5,185,258.

5 "Non-human subtilisins" and the DNA encoding them may be obtained from many procaryotic and eucaryotic organisms. Suitable examples of procaryotic organisms include gram negative organisms such as *E. coli* or *Pseudomonas* and gram positive bacteria such as *Micrococcus* or *Bacillus*. Examples of eucaryotic organisms from which subtilisin and their genes may be obtained include yeast such as *Saccharomyces*

10 *cerevisiae*, fungi such as *Aspergillus* sp.

"Human subtilisin" means the protein represented by the sequence in Fig. 6, derivatives thereof or modifications thereof which retain the essential ability to hydrolyze peptide bonds.


15 A "protease variant" has an amino acid sequence which is derived from the amino acid sequence of a "precursor protease". The precursor proteases include naturally-occurring proteases and recombinant proteases. The amino acid sequence of the protease variant is "derived" from the precursor protease amino acid sequence by the substitution, deletion or insertion of one or more amino acids of the precursor amino acid sequence. Such modification is of the "precursor DNA sequence" which encodes the

20 amino acid sequence of the precursor protease rather than manipulation of the precursor protease enzyme *per se*. Suitable methods for such manipulation of the precursor DNA sequence include methods disclosed herein, as well as methods known to those skilled in the art (see, for example, EP 0 328299, WO89/06279 and the US patents and applications already referenced herein).

25 These amino acid position numbers used herein refer to those assigned to the mature *Bacillus amyloliquefaciens* subtilisin sequence presented in Fig. 1. The invention, however, is not limited to the mutation of this particular subtilisin but extends to precursor proteases containing amino acid residues at positions which are "equivalent" to the particular identified residues in *Bacillus amyloliquefaciens* subtilisin. In a preferred

30 embodiment of the present invention, the precursor protease is *Bacillus lenthus* subtilisin and the substitutions, deletions or insertions are made at the equivalent amino acid residue in *B. lenthus* corresponding to those listed above.

35 A residue (amino acid) of a precursor protease is equivalent to a residue of *Bacillus amyloliquefaciens* subtilisin if it is either homologous (i.e., corresponding in




position in either primary or tertiary structure) or analogous to a specific residue or portion of that residue in *Bacillus amyloliquefaciens* subtilisin (i.e., having the same or similar functional capacity to combine, react, or interact chemically).

In order to establish homology to primary structure, the amino acid sequence of a precursor protease is directly compared to the *Bacillus amyloliquefaciens* subtilisin primary sequence and particularly to a set of residues known to be invariant in subtilisins for which sequence is known. For example, Fig. 2 herein shows the conserved residues as between *B. amyloliquefaciens* subtilisin and *B. lenthus* subtilisin. After aligning the conserved residues, allowing for necessary insertions and deletions in order to maintain alignment (i.e., avoiding the elimination of conserved residues through arbitrary deletion and insertion), the residues equivalent to particular amino acids in the primary sequence of *Bacillus amyloliquefaciens* subtilisin are defined. Alignment of conserved residues preferably should conserve 100% of such residues. However, alignment of greater than 75% or as little as 50% of conserved residues is also adequate to define equivalent residues. Conservation of the catalytic triad, Asp32/His64/Ser221 should be maintained.

For example, in Fig. 6 the amino acid sequence of subtilisin from *Bacillus amyloliquefaciens*, *Bacillus subtilis*, *Bacillus licheniformis* (carlsbergensis) and *Bacillus lenthus* are aligned to provide the maximum amount of homology between amino acid sequences. A comparison of these sequences shows that there are a number of conserved residues contained in each sequence. These conserved residues (as between BPN' and *B. lenthus*) are identified in Fig. 2.

These conserved residues, thus, may be used to define the corresponding equivalent amino acid residues of *Bacillus amyloliquefaciens* subtilisin in other subtilisins such as subtilisin from *Bacillus lenthus* (PCT Publication No. W089/06279 published July 25, 1989), the preferred protease precursor enzyme herein, or the subtilisin referred to as PB92 (EP 0 328 299), which is highly homologous to the preferred *Bacillus lenthus* subtilisin. The amino acid sequences of certain of these subtilisins are aligned in Figs. 3A and 3B with the sequence of *Bacillus amyloliquefaciens* subtilisin to produce the maximum homology of conserved residues. As can be seen, there are a number of deletions in the sequence of *Bacillus lenthus* as compared to *Bacillus amyloliquefaciens* subtilisin. Thus, for example, the equivalent amino acid for Val165 in *Bacillus amyloliquefaciens* subtilisin in the other subtilisins is isoleucine for *B. lenthus* and *B. licheniformis*.

Thus, for example, the amino acid at position +170 is lysine (K) in both *B. amyloliquefaciens* and *B. licheniformis* subtilisins and arginine (R) in Savinase. In the 35 protease variants of the invention, however, the amino acid equivalent to +170 in *Bacillus*




amyloliquefaciens subtilisin is substituted with aspartic acid (D). The abbreviations and one letter codes for all amino acids in the present invention conform to the PatentIn User Manual (GenBank, Mountain View, CA) 1990, p.101.

"Equivalent residues" may also be defined by determining homology at the level of 5 tertiary structure for a precursor protease whose tertiary structure has been determined by x-ray crystallography. Equivalent residues are defined as those for which the atomic coordinates of two or more of the main chain atoms of a particular amino acid residue of the precursor protease and *Bacillus amyloliquefaciens* subtilisin (N on N, CA on CA, C on C and O on O) are within 0.13nm and preferably 0.1nm after alignment. Alignment is 10 achieved after the best model has been oriented and positioned to give the maximum overlap of atomic coordinates of non-hydrogen protein atoms of the protease in question to the *Bacillus amyloliquefaciens* subtilisin. The best model is the crystallographic model giving the lowest R factor for experimental diffraction data at the highest resolution available.

15

$$R \text{ factor} = \frac{\sum_h |F_o(h)| - |F_c(h)|}{\sum_h |F_o(h)|}$$

Equivalent residues which are functionally analogous to a specific residue of *Bacillus amyloliquefaciens* subtilisin are defined as those amino acids of the precursor protease which may adopt a conformation such that they either alter, modify or contribute to protein structure, substrate binding or catalysis in a manner defined and attributed to a 20 specific residue of the *Bacillus amyloliquefaciens* subtilisin. Further, they are those residues of the precursor protease (for which a tertiary structure has been obtained by x-ray crystallography) which occupy an analogous position to the extent that, although the main chain atoms of the given residue may not satisfy the criteria of equivalence on the basis of occupying a homologous position, the atomic coordinates of at least two of the 25 side chain atoms of the residue lie with 0.13nm of the corresponding side chain atoms of *Bacillus amyloliquefaciens* subtilisin. The coordinates of the three dimensional structure of *Bacillus amyloliquefaciens* subtilisin are set forth in EPO Publication No. 0 251 446 (equivalent to US Patent 5,182,204, the disclosure of which is incorporated herein by reference) and can be used as outlined above to determine equivalent residues on the 30 level of tertiary structure.




Some of the residues identified for substitution, insertion or deletion are conserved residues whereas others are not. In the case of residues which are not conserved, the replacement of one or more amino acids is limited to substitutions which produce a variant which has an amino acid sequence that does not correspond to one found in nature. In 5 the case of conserved residues, such replacements should not result in a naturally- occurring sequence. The protease variants of the present invention include the mature forms of protease variants, as well as the pro- and prepro-forms of such protease variants. The prepro-forms are the preferred construction since this facilitates the expression, secretion and maturation of the protease variants.

10 "Prosequence" refers to a sequence of amino acids bound to the N-terminal portion of the mature form of a protease which when removed results in the appearance of the "mature" form of the protease. Many proteolytic enzymes are found in nature as translational proenzyme products and, in the absence of post-translational processing, are expressed in this fashion. A preferred prosequence for producing protease variants is the 15 putative prosequence of *Bacillus amyloliquefaciens* subtilisin, although other protease prosequences may be used.

A "signal sequence" or "presequence" refers to any sequence of amino acids bound to the N-terminal portion of a protease or to the N-terminal portion of a proprotease which may participate in the secretion of the mature or pro forms of the protease. This 20 definition of signal sequence is a functional one, meant to include all those amino acid sequences encoded by the N-terminal portion of the protease gene which participate in the effectuation of the secretion of protease under native conditions. The present invention utilizes such sequences to effect the secretion of the protease variants as defined herein. One possible signal sequence comprises the first seven amino acid 25 residues of the signal sequence from *Bacillus subtilis* subtilisin fused to the remainder of the signal sequence of the subtilisin from *Bacillus lenthus* (ATCC 21536).

A "prepro" form of a protease variant consists of the mature form of the protease having a prosequence operably linked to the amino terminus of the protease and a "pre" or "signal" sequence operably linked to the amino terminus of the prosequence.

30 "Expression vector" refers to a DNA construct containing a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of said DNA in a suitable host. Such control sequences include a promoter to effect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites and sequences which control termination of transcription 35 and translation. The vector may be a plasmid, a phage particle, or simply a potential



genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, in some instances, integrate into the genome itself. In the present specification, "plasmid" and "vector" are sometimes used interchangeably as the plasmid is the most commonly used form of vector at present.

5 However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which are, or become, known in the art.


The "host cells" used in the present invention generally are prokaryotic or eucaryotic hosts which preferably have been manipulated by the methods disclosed in US Patent 4,760,025 (RE 34,606) to render them incapable of secreting enzymatically active 10 endoprotease. A preferred host cell for expressing protease is the *Bacillus* strain BG2036 which is deficient in enzymatically active neutral protease and alkaline protease (subtilisin). The construction of strain BG2036 is described in detail in US Patent 5,264,366. Other host cells for expressing protease include *Bacillus subtilis* I168 (also 15 described in US Patent 4,760,025 (RE 34,606) and US Patent 5,264,366, the disclosure of which are incorporated herein by reference), as well as any suitable *Bacillus* strain such as *B. licheniformis*, *B. lentus*, etc.

Host cells are transformed or transfected with vectors constructed using recombinant DNA techniques. Such transformed host cells are capable of either 20 replicating vectors encoding the protease variants or expressing the desired protease variant. In the case of vectors which encode the pre- or prepro-form of the protease variant, such variants, when expressed, are typically secreted from the host cell into the host cell medium.

"Operably linked," when describing the relationship between two DNA regions, simply means that they are functionally related to each other. For example, a 25 presequence is operably linked to a peptide if it functions as a signal sequence, participating in the secretion of the mature form of the protein most probably involving cleavage of the signal sequence. A promoter is operably linked to a coding sequence if it controls the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to permit translation.

30 The genes encoding the naturally-occurring precursor protease may be obtained in accord with the general methods known to those skilled in the art. The methods generally comprise synthesizing labeled probes having putative sequences encoding regions of the protease of interest, preparing genomic libraries from organisms expressing the protease, and screening the libraries for the gene of interest by hybridization to the probes.

35 Positively hybridizing clones are then mapped and sequenced.




The cloned protease is then used to transform a host cell in order to express the protease. The protease gene is then ligated into a high copy number plasmid. This plasmid replicates in hosts in the sense that it contains the well-known elements necessary for plasmid replication: a promoter operably linked to the gene in question (which may be supplied as the gene's own homologous promoter if it is recognized, i.e., transcribed, by the host), a transcription termination and polyadenylation region (necessary for stability of the mRNA transcribed by the host from the protease gene in certain eucaryotic host cells) which is exogenous or is supplied by the endogenous 5 terminator region of the protease gene and, desirably, a selection gene such as an antibiotic resistance gene that enables continuous cultural maintenance of plasmid-infected host cells by growth in antibiotic-containing media. High copy number plasmids 10 also contain an origin of replication for the host, thereby enabling large numbers of plasmids to be generated in the cytoplasm without chromosomal limitations. However, it is within the scope herein to integrate multiple copies of the protease gene into host genome. This is facilitated by procaryotic and eucaryotic organisms which are particularly 15 susceptible to homologous recombination.

In one embodiment, the gene can be a natural gene such as that from *B. lenthus* or *B. amyloliquefaciens*. Alternatively, a synthetic gene encoding a naturally-occurring or mutant precursor protease may be produced. In such an approach, the DNA and/or 20 amino acid sequence of the precursor protease is determined. Multiple, overlapping synthetic single-stranded DNA fragments are thereafter synthesized, which upon hybridization and ligation produce a synthetic DNA encoding the precursor protease. An example of synthetic gene construction is set forth in Example 3 of US Patent 5,204,015, the disclosure of which is incorporated herein by reference.

25 Once the naturally-occurring or synthetic precursor protease gene has been cloned, a number of modifications are undertaken to enhance the use of the gene beyond synthesis of the naturally-occurring precursor protease. Such modifications include the production of recombinant proteases as disclosed in US Patent 4,760,025 (RE 34,606) and EPO Publication No. 0 251 446 and the production of protease variants described 30 herein.

The following cassette mutagenesis method may be used to facilitate the construction of the protease variants of the present invention, although other methods may be used. First, the naturally-occurring gene encoding the protease is obtained and sequenced in whole or in part. Then the sequence is scanned for a point at which it is 35 desired to make a mutation (deletion, insertion or substitution) of one or more amino acids



in the encoded enzyme. The sequences flanking this point are evaluated for the presence of restriction sites for replacing a short segment of the gene with an oligonucleotide pool which when expressed will encode various mutants. Such restriction sites are preferably unique sites within the protease gene so as to facilitate the replacement of the gene

5 segment. However, any convenient restriction site which is not overly redundant in the protease gene may be used, provided the gene fragments generated by restriction digestion can be reassembled in proper sequence. If restriction sites are not present at locations within a convenient distance from the selected point (from 10 to 15 nucleotides), such sites are generated by substituting nucleotides in the gene in such a fashion that

10 neither the reading frame nor the amino acids encoded are changed in the final construction. Mutation of the gene in order to change its sequence to conform to the desired sequence is accomplished by M13 primer extension in accord with generally known methods. The task of locating suitable flanking regions and evaluating the needed changes to arrive at two convenient restriction site sequences is made routine by the

15 redundancy of the genetic code, a restriction enzyme map of the gene and the large number of different restriction enzymes. Note that if a convenient flanking restriction site is available, the above method need be used only in connection with the flanking region which does not contain a site.


Once the naturally-occurring DNA or synthetic DNA is cloned, the restriction sites flanking the positions to be mutated are digested with the cognate restriction enzymes and a plurality of end termini-complementary oligonucleotide cassettes are ligated into the gene. The mutagenesis is simplified by this method because all of the oligonucleotides can be synthesized so as to have the same restriction sites, and no synthetic linkers are necessary to create the restriction sites.

25 In one aspect of the invention, the objective is to secure a variant protease having altered allergenic potential as compared to the precursor protease, since decreasing such potential enables safer use of the enzyme. While the instant invention is useful to lower allergenic potential, the mutations specified herein may be utilized in combination with mutations known in the art to result altered thermal stability and/or altered substrate

30 specificity, modified activity or altered alkaline stability as compared to the precursor.

Thus, in combination with the mutations of the present invention, substitutions at positions corresponding to N76D/S103A/V104I/G159D optionally in combination with one or more substitutions selected from the group consisting of positions corresponding to V68A, T213R, A232V, Q236H, Q245R, and T260A of *Bacillus amyloliquefaciens* subtilisin

35 may be used, in addition to decreasing the allergenic potential of the variant protease of




the invention, to modulate overall stability and/or proteolytic activity of the enzyme. Similarly, the substitutions provided herein may be combined with mutation at the Asparagine (N) in *Bacillus lenthus* subtilisin at equivalent position +76 to Aspartate (D) in combination with the mutations S103A/V104I/G159D and optionally in combination with 5 one or more substitutions selected from the group consisting of positions corresponding to V68A, T213R, A232V, Q236H, Q245R, and T260A of *Bacillus amyloliquefaciens* subtilisin, to produce enhanced stability and/or enhanced activity of the resulting mutant enzyme.

Based on the screening results obtained with the variant proteases, the noted 10 mutations in *Bacillus amyloliquefaciens* subtilisin are important to the proteolytic activity, performance and/or stability of these enzymes and the cleaning or wash performance of such variant enzymes.

Many of the protease variants of the invention are useful in formulating various detergent compositions. A number of known compounds are suitable surfactants useful in compositions comprising the protease mutants of the invention. These include nonionic, 15 anionic, cationic, anionic or zwitterionic detergents, as disclosed in US 4,404,128 to Barry J. Anderson and US 4,261,868 to Jiri Flora, et al. A suitable detergent formulation is that described in Example 7 of US Patent 5,204,015 (previously incorporated by reference). The art is familiar with the different formulations which can be used as cleaning 20 compositions. In addition to typical cleaning compositions, it is readily understood that the protease variants of the present invention may be used for any purpose that native or wild-type proteases are used. Thus, these variants can be used, for example, in personal care items such as face lotions and cosmetics, in bar or liquid soap applications, dishcare 25 formulations, contact lens cleaning solutions or products, peptide hydrolysis, waste treatment, textile applications, as fusion-cleavage enzymes in protein production, etc. The variants of the present invention may comprise enhanced performance in a detergent composition (as compared to the precursor). As used herein, enhanced performance in a detergent is defined as increasing cleaning of certain enzyme sensitive stains such as grass or blood, as determined by usual evaluation after a standard wash cycle.

Proteases of the invention can be formulated into known powdered and liquid 30 detergents having pH between 6.5 and 12.0 at levels of about .01 to about 5% (preferably .1% to .5%) by weight. These detergent cleaning compositions can also include other enzymes such as known proteases, amylases, cellulases, lipases or endoglycosidases, as well as builders and stabilizers.

The addition of proteases of the invention to conventional cleaning compositions 35 does not create any special use limitation. In other words, any temperature and pH



suitable for the detergent is also suitable for the present compositions as long as the pH is within the above range, and the temperature is below the described protease's denaturing temperature. In addition, proteases of the invention can be used in a cleaning composition without detergents, again either alone or in combination with builders and

5 stabilizers.

The variant proteases of the present invention can be included in animal feed such as part of animal feed additives as described in, for example, US 5,612,055; US 5,314,692; and US 5,147,642.

One aspect of the invention is a composition for the treatment of a textile that

10 includes variant proteases of the present invention. The composition can be used to treat for example silk or wool as described in publications such as RD 216,034; EP 134,267; US 4,533,359; and EP 344,259.

The following is presented by way of example and is not to be construed as a limitation to the scope of the claims.

15 All publications and patents referenced herein are hereby incorporated by reference in their entirety.

EXAMPLES


Example 1

20 **Assay for the Identification of Peptide T-Cell Epitopes**
Using Naïve Human T-Cells

Fresh human peripheral blood cells were collected from "naïve" humans, i.e., persons not known to be exposed to or sensitized to *Bacillus lentinus* protease, for determination of antigenic epitopes in protease from *Bacillus lentinus* and human subtilisin.

25 Naïve humans is intended to mean that the individual is not known to have been exposed to or developed a reaction to protease in the past. Peripheral mononuclear blood cells (stored at room temperature, no older than 24 hours) were prepared for use as follows: Approximately 30 mls of a solution of buffy coat preparation from one unit of whole blood was brought to 50 ml with Dulbecco's phosphate buffered solution (DPBS) and split into

30 two tubes. The samples were underlaid with 12.5 ml of room temperature lymphoprep density separation media (Nycomed density 1.077 g/ml). The tubes were centrifuged for thirty minutes at 600G. The interface of the two phases was collected, pooled and washed in DPBS. The cell density of the resultant solution was measured by hemocytometer. Viability was measured by trypan blue exclusion.



From the resulting solution, a differentiated dendritic cell culture was prepared from the peripheral blood mononuclear cell sample having a density of 10^8 cells per 75 ml culture flask in a solution as follows:

(1) 50 ml of serum free AIM V media (Gibco) was supplemented with a 5 1:100 dilution beta-mercaptoethanol (Gibco). The flasks were laid flat for two hours at 37°C in 5% CO₂ to allow adherence of monocytes to the flask wall.


(2) Differentiation of the monocyte cells to dendritic cells was as follows: nonadherent cells were removed and the resultant adherent cells (monocytes) combined with 30 ml of AIM V, 800 units/ml of GM-CSF (Endogen) 10 and 500 units/ml of IL-4 (Endogen); the resulting mixture was cultured for 5 days under conditions at 37°C in 5% CO₂. After five days, the cytokine TNF(α) (Endogen) was added to 0.2 units/ml, and the cytokine IL-1α (Endogen) was added to a final concentration of 50 units/ml and the mixture incubated at 37°C in 5% CO₂ for two more days.

(3) On the seventh day, Mitomycin C was added to a concentration of 15 50 microgram/ml was added to stop growth of the now differentiated dendritic cell culture. The solution was incubated for 60 minutes at 37°C in 5% CO₂. Dendritic cells were collected by gently scraping the adherent cells off the bottom of the flask with a cell scraper. Adherent and non-adherent cells were then centrifuged at 20 600G for 5 minutes, washed in DPBS and counted.

(4) The prepared dendritic cells were placed into a 96 well round bottom array at 2×10^4 /well in 100 microliter total volume.

CD4+ T cells were prepared from frozen aliquots of the peripheral blood cell samples used to prepare the dendritic cells using the human CD4+ Cellect Kit (Biotex) as 25 per the manufacturers instructions with the following modifications: the aliquots were thawed and washed such that approximately 10^8 cells will be applied per Cellect column; the cells were resuspended in 4 ml DPBS and 1 ml of the Cell reagent from the Cellect Kit, the solution maintained at room temperature for 20 minutes. The resultant solution was centrifuged for five minutes at 600G at room temperature and the pellet resuspended in 2 30 ml of DPBS and applied to the Cellect columns. The effluent from the columns was collected in 2% human serum in DPBS. The resultant CD4+ cell solution was centrifuged, resuspended in AIMV media and the density counted.

The CD4+ T-cell suspension was resuspended to a count of 2×10^6 /ml in AIM V media to facilitate efficient manipulation of the 96 well plate.



Peptide antigen is prepared from a 1M stock solution in DMSO by dilution in AIM V media at a 1:10 ratio. 10 microliters of the stock solution is placed in each well of the 96 well plate containing the differentiated dendritic cells. 100 microliter of the diluted CD4+ T-cell solution as prepared above is further added to each well. Useful controls include 5 diluted DMSO blanks, and tetanus toxoid positive controls.

The final concentrations in each well, at 210 microliter total volume are as follows:

2x10⁵ CD4+

2x10⁴ dendritic cells (R:S of 10:1)

5 mM/10⁴ peptide

10

Example 2

Identification of T-Cell Epitopes in Protease from *Bacillus lentinus* and Human subtilisin

Peptides for use in the assay described in Example 1 were prepared based on the


15 *Bacillus lentinus* and human subtilisin amino acid sequence. Peptide antigens were designed as follows. From the full length amino acid sequence of either human subtilisin or *Bacillus lentinus* protease provided in Figure 1, 15mers were synthetically prepared, each 15mer overlapping with the previous and the subsequent 15mer except for three residues.

Peptides used correspond to amino acid residue strings in *Bacillus lentinus* as


20 provided in Figure 7, and peptides correspond to amino acid residues in *human subtilisin* as provided in Figure 8. The key for the coded results is provided in Figure 10. All tests were performed at least in duplicate. All tests reported displayed robust positive control responses to the antigen tetanus toxoid. Responses were averaged within each experiment, then normalized to the baseline response. A positive event was recorded if 25 the response was at least 3 times the baseline response.

The immunogenic response (i.e., T-cell proliferation) to the prepared peptides from human subtilisin and *Bacillus lentinus* was tallied and is provided in Figures 4 and 5, respectively. T-cell proliferation was measured by the incorporated tritium method. The 30 results shown in Figures 4 and 5 as a comparison of the immunogenic additive response in 10 individuals (figure 4) and 16 individuals (figure 5) to the various peptides. Response is indicated as the added response wherein 1.0 equals a baseline response for each sample. Thus, in Figure 4, a reading of 10.0 or less is the baseline response and in Figure 5 a reading of 16.0 or less the baseline response.

10/20/99
11/1/99




As indicated in Figures 4 and 5, the immunogenic response of the naïve blood samples from unsensitized individuals showed a marked allergenic response at the peptide fragment from *Bacillus lenthus* corresponding to residues 170-173 of *Bacillus amyloliquefaciens* protease. As expected, the corresponding fragment in human subtilisin 5 evokes merely baseline response.



WE CLAIM:

1. A method for reducing the allergenicity of a non-human protein is provided wherein an epitope is identified and replaced with an analogous region within a human subtilisin.
- 5 2. The method according to claim 1, wherein said non-human protein comprises a protease.
3. The method according to claim 2, wherein said epitope replaced is a T-cell epitope.
4. A method for producing the protein of the invention having reduced allergenicity
- 10 comprising, preparing a mutant protein by modifying a DNA encoding a precursor protein so that the modified DNA encodes the mutant protein of the invention, wherein an epitope is replaced with an analogous region from human subtilisin.
5. A mutant protein having reduced allergenicity produced according to the method of claim 4.
- 15 6. DNA encoding the mutant protein of claim 5.
7. An expression vector containing a DNA sequence according to claim 6.
8. Host cells transformed with the vectors of claim 7.
9. A method of producing a protein having reduced allergenicity wherein the host
- 15 cells of claim 8 are cultivated under conditions which result in expression of the mutant
- 20 protease.
10. A pharmaceutical composition comprising a human subtilisin.
11. A DNA encoding a human subtilisin.
12. A vector comprising the DNA of claim 11.
13. A host cell comprising the vector of claim 12.
- 25 14. A human subtilisin produced by the host cell of claim 12.






FIG._ 1A






FIG. 1B-1



| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|
| 549 | GCA | GCG | GGG | GCA | GGC | AGC | ATG | GTT | CCT | TCT | GAA | ACA | AAT | CCT | GGT | GAA | ATC | GGT | ATC | GGT | GAA | ATC | GGT | GCA | ACT | CAC | GTT | CCC | | | |
| 624 | GCC | ACA | GTT | GCG | GCT | CTT | AAT | AAC | TCA | ATC | GGT | GTA | TTA | GCC | GTT | GCA | AGC | CCA | GGG | CCA | GGC | ATC | GAG | TGG | GCG | ATC | GCA | AAC | AAT | GTA | AAA |
| 699 | GTT | CTC | GGT | GCT | GAC | GGT | TCC | GGC | CAA | TAC | AGC | TGG | ATC | ATT | AAC | GGA | ATC | GAG | TGG | GCG | ATC | GCA | AAC | AAT | ATG | | | | | | |
| 774 | GAC | GTT | ATT | AAC | ATG | AGC | CTC | GGC | GGA | CCT | TCT | GGT | TCT | GCT | GCT | GCA | GGC | ACT | TCC | GGC | AGC | TCA | AGC | ACA | GTC | GGC | TAC | CCT | GGT | | |
| 849 | TCC | GGC | GTC | GTC | GTC | GTC | GTT | GGG | GCA | GGC | GGT | AAC | GAA | GGG | ACT | TCC | GGC | AGC | TCA | AGC | GGC | AGC | TCA | AGC | GTC | GGC | TAC | CCT | GGT | | |
| 924 | AAA | TAC | CCT | TCT | GTC | ATT | GCA | GTA | GGC | GCT | GTT | GAC | AGC | AGC | AAAC | CAA | AGA | GCA | TCT | TTC | TCA | AGC | GTC | GGA | CCCT | | | | | | |
| 999 | GAG | CTT | GAT | GTC | ATG | GCA | CCT | GGC | GTA | TCT | ATC | CAN | AGC | AGC | CTT | CCT | GGA | AGC | AAA | TAC | GGG | GCG | TAC | MAC | GGT | | | | | | |
| 1074 | ACG | TCA | ATG | GCA | TCT | CCG | CAC | GTC | GCT | GCG | GCG | GGA | GCG | GCT | GCT | TGG | ATT | CCT | TCT | AAG | CAC | CCG | AAC | TGG | ACA | AAC | ACT | | | | |

FIG.-1B - 2



| | | | | | | | | | | | | | | | | | | | | | | | | | |
|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| 1149 | Gln | Val | Arg | Ser | Ser | 250 | Gln | Glu | Asn | Thr | Thr | Lys | Leu | Gly | Asp | Phe | Tyr | Tyr | Gly | Lys | Leu | Ile | Asn | | |
| | CAA | GTC | CGC | AGC | AGT | TTA | GAA | AAC | ACC | ACT | ACA | AAA | CTT | GAT | TCT | GGT | TAT | TAC | TAC | TTC | TAC | TAT | GGA | AAA | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1224 | 270 | Val | Gln | Ala | Ala | 275 | Gln | OC | | | | | | | | | | | | | | | | | |
| | | GTA | CAG | GCG | GCA | GCT | CAG | TAA | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | |

1224 **TERM**
 1316 ATAATCGACGGATGGCTCCCTCTGAAATTAAACGAGAAACGGGAAACGGGGTTGACCCGGCTAGTCCGTAAACGGCAAGTCTGAAACGTCATAATCGCCG

1416 CTTCCCGGTTCCGGTCAATGCCGTAACGGTCCGGCTTCTGATAACGGGAGCGGATTCTGATAACGGGATTCGGATC

FIG.-1B - 3

FIG.-1B - 1

FIG.-1B - 2

FIG.-1B - 3

FIG.-1B




5/13

CONSERVED RESIDUES IN SUBTILISINS FROM
BACILLUS AMYLOLIQUEFACIENS

| | | |
|---|-----------------|-----|
| 1 | 10 | 20 |
| A Q S V P . G | A P A . H . . G | |
| 21 | 30 | 40 |
| . T G S . V K V A V . D . G H P | | |
| 41 | 50 | 60 |
| D L . . . G G A S . V P Q D | | |
| 61 | 70 | 80 |
| . N . H G T H V A G T . A A L N N S I G | | |
| 81 | 90 | 100 |
| V L G V A P S A . L Y A V K V L G A . G | | |
| 101 | 110 | 120 |
| S G . . S . L . . G . E W A . N . . . | | |
| 121 | 130 | 140 |
| V . N . S L G . P S . S A . . | | |
| 141 | 150 | 160 |
| G V . V V A A . G N . G . . . | | |
| 161 | 170 | 180 |
| Y P . . Y A V G A . | | |
| 181 | 190 | 200 |
| D . . N . . A S F S . . G . . L D . . A | | |
| 201 | 210 | 220 |
| P G V . . Q S T . P G . . Y . . . N G T | | |
| 221 | 230 | 240 |
| S M A . P H V A G A A L . . . K . . . | | |
| 241 | 250 | 260 |
| W . . . Q . R . . L . N T . . . L G . . . | | |
| 261 | 270 | |
| . . Y G . G L . N . . A A . . | | |

FIG._2




6/13

COMPARISON OF SUBTILISIN SEQUENCES FROM:

*B. amyloliquefaciens**B. subtilis**B. licheniformis**B. lentus*

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 01 | 10 | 20 | 30 | 40 | 50 | 60 | 70 |
| A Q S V P Y G V S Q I K A P A L H S Q G Y T G S N V K V A I D S G I D S S H P | A Q S V P Y G I S Q I K A P A L H S Q G Y T G S N V K V A I D S G I D S S H P | A Q T V P Y G I P L I K A D K V Q A Q G F K G A N V K V A V L D T G I Q A S H P | A Q S V P W G I S R V Q A P A H N R G L T G S G V K V A V L D T G I S T * H P | D L R V A G G A S M V P S E T N P P Q D N N S H G T H V A G T V A A L N N S I G | D L N V R G G A S P V P S E T N P Y Q D G S S H G T H V A G T I A A L N N S I G | D L N V V G G A S P V A G E A Y N * T D G N G H G T H V A G T V A A L D N T T G | D L N I R G G A S P V P G E * P S T Q D G N G H G T H V A G T I A A L N N S I G |
| 81 | 90 | 100 | 110 | 121 | 130 | 140 | 150 |
| V L G V A P S A S S L Y A V K V L G A D G S G Q Y S W I I N G I E W A I A N N M D | V L G V S P S A S S L Y A V K V L D S T G S G Q Y S W I I N G I E W A I S N M D | V L G V A P S V S L Y A V K V L N S S G S G S Y S G I V S G I E W A T T N G M D | V L G V A P S A E L Y A V K V L G A S S G S V S S T I A Q G L E W A G N N G M H | V I N M S S L G G P S G S A A L K A A V D K A V A S G V V V A A A G N E G T S G | V I N M S S L G G P T G S T A L K T V V D K A V S S G I V V A A A G N E G S S G | V I N M S S L G G A S S G S T A M K Q A V D N A Y A R G V V V A A A G N S G N S G | V A N L S L G S P S P S A T L E Q A V N S A T S R G V L V V A A S G N S G A G S |

FIG.-3A



7/13


161 S S T V G Y P G K Y P S V I A V G A V D S S N Q R A S P S S V G P E L D V M A
 S T S T V G Y P A K Y P S T I A V G A V N Q R A S F S S A G S E L D V M A
 S T N T I G Y P A K Y D S V I A V G A V D S S N N R A S F S S V G A E L E V M A
 * * * * * I S Y P A R Y A N A M A V G A T D Q N N N R A S F S S Q Y G A G L D I V A
 170 S S T V G Y P G K Y P S V I A V G A V D S S N Q R A S P S S V G P E L D V M A
 S T S T V G Y P A K Y P S T I A V G A V N Q R A S F S S A G S E L D V M A
 S T N T I G Y P A K Y D S V I A V G A V D S S N N R A S F S S V G A E L E V M A
 180 P G V S I Q S T L P G N K Y G A Y N G T S M A S P H V A G A A A L I L S K H P N
 P G V S I Q S T L P G G T Y G A Y N G T S M A T P H V A G A A A L I L S K H P T
 P G A G V Y S T Y P T N T Y A T L N G T S M A S P H V A G A A A L I L S K H P N
 P G V N V Q S T Y P G S T Y P S L N G T S M A T P H V A G A A A L V K Q R N P S
 190 P G V S I Q S T L P G N K Y G A Y N G T S M A S P H V A G A A A L I L S K H P N
 P G V S I Q S T L P G G T Y G A Y N G T S M A T P H V A G A A A L I L S K H P T
 P G A G V Y S T Y P T N T Y A T L N G T S M A S P H V A G A A A L I L S K H P N
 P G V N V Q S T Y P G S T Y P S L N G T S M A T P H V A G A A A L V K Q R N P S
 201 P G V S I Q S T L P G N K Y G A Y N G T S M A S P H V A G A A A L I L S K H P N
 P G V S I Q S T L P G G T Y G A Y N G T S M A T P H V A G A A A L I L S K H P T
 P G A G V Y S T Y P T N T Y A T L N G T S M A S P H V A G A A A L I L S K H P N
 P G V N V Q S T Y P G S T Y P S L N G T S M A T P H V A G A A A L V K Q R N P S
 210 P G V S I Q S T L P G N K Y G A Y N G T S M A S P H V A G A A A L I L S K H P N
 P G V S I Q S T L P G G T Y G A Y N G T S M A T P H V A G A A A L I L S K H P T
 P G A G V Y S T Y P T N T Y A T L N G T S M A S P H V A G A A A L I L S K H P N
 P G V N V Q S T Y P G S T Y P S L N G T S M A T P H V A G A A A L V K Q R N P S
 220 P G V S I Q S T L P G N K Y G A Y N G T S M A S P H V A G A A A L I L S K H P N
 P G V S I Q S T L P G G T Y G A Y N G T S M A T P H V A G A A A L I L S K H P T
 P G A G V Y S T Y P T N T Y A T L N G T S M A S P H V A G A A A L I L S K H P N
 P G V N V Q S T Y P G S T Y P S L N G T S M A T P H V A G A A A L V K Q R N P S
 230 P G V S I Q S T L P G N K Y G A Y N G T S M A S P H V A G A A A L I L S K H P N
 P G V S I Q S T L P G G T Y G A Y N G T S M A T P H V A G A A A L I L S K H P T
 P G A G V Y S T Y P T N T Y A T L N G T S M A S P H V A G A A A L I L S K H P N
 P G V N V Q S T Y P G S T Y P S L N G T S M A T P H V A G A A A L V K Q R N P S
 241 W T N T Q V R S S L E N T T K L G D S F Y Y G K G L I N V Q A A A Q
 W T N A Q V R D R L E S T A T Y L G N S F Y Y G K G L I N V Q A A A Q
 L S A S Q V R N R L S S T A T Y L G S S F Y Y G K G L I N V E A A A Q
 W S N V Q I R N H L K N T A T S L G S T N L Y G S G L V N A E A A T R
 250 W T N T Q V R S S L E N T T K L G D S F Y Y G K G L I N V Q A A A Q
 W T N A Q V R D R L E S T A T Y L G N S F Y Y G K G L I N V Q A A A Q
 L S A S Q V R N R L S S T A T Y L G S S F Y Y G K G L I N V E A A A Q
 W S N V Q I R N H L K N T A T S L G S T N L Y G S G L V N A E A A T R
 260 W T N T Q V R S S L E N T T K L G D S F Y Y G K G L I N V Q A A A Q
 W T N A Q V R D R L E S T A T Y L G N S F Y Y G K G L I N V Q A A A Q
 L S A S Q V R N R L S S T A T Y L G S S F Y Y G K G L I N V E A A A Q
 W S N V Q I R N H L K N T A T S L G S T N L Y G S G L V N A E A A T R
 270 W T N T Q V R S S L E N T T K L G D S F Y Y G K G L I N V Q A A A Q
 W T N A Q V R D R L E S T A T Y L G N S F Y Y G K G L I N V Q A A A Q
 L S A S Q V R N R L S S T A T Y L G S S F Y Y G K G L I N V E A A A Q
 W S N V Q I R N H L K N T A T S L G S T N L Y G S G L V N A E A A T R

FIG.-3B

FIG.-3

FIG.-3A

FIG.-3B







FIG. 4







FIG. 5




10/13

MKLVNIWLLLIVVLLCGKKHLGDRLEKKSFEKAPCPGCSHLTLKVEFSSSTVVEYEYIVAFNGYFT
AKARNSFISSALKSSEVDNWRIIPRNNPSSDYPSSDPEVIQIKEKQKAGLLTLEDHPNIKRVTPQR
KVFRSLKYAESDPTVPCNETRWSQKQSSRPLRASLSLGSGFWHATGRHSSRLLRAI PRQVAQ
TLQADVLWQMGYTGANVRVAVFDTGLSEKHPFKNVKERTNWTNERTLDDGLGHGTFVAGVIASM
RECQGFAPDAELHIFRVFTNNQSYTSWFLDAFNYA1LKKIDVNLISIGGPDFMDHPFVDKVWEL
TANNVIMVSAIGNDGPLYGTLNNPADQMDVIGVGGIDFEDNIARFSSRGMTTWELPGGYGRMKPD
TVTYCAGVRGSGVKGCCRALS GTSVASPVVAGAVTLLVSTVQKRELVNPASMQALIASARRLPG
VNMFEQGHGKLDLLRAYQILNSYKPQASLSPSYIDLTECPYMWPYCSQPIYYGGMPTVNVTLN
GMGVTGRIVDKPDWQPYLPQNGDNIEVAFSYSSVLWPWSGYLAISISVTKKAASWEGLAQGHVMI
TVASPAETESKNAGEQTSTVKLPIKVIIIPTPPRSKRVLWDQYHNLRYPPGYFPRDNLRMKNDPL
DWNGDHIHTNFRDMYQHLSRSGYFVEVLGAPFTCFDASOYGTLLMVDSEEEYFPEEIAKLRDVD
NGLSLVIFSDWYNTSVMRKVKFYDENTRQWMPDTGGANI PALNELLSVWNMGFSDGLYEGEFTL
ANHDMYYASGCSIAKFPEDGVVITQTFKDQGLEVLKQETAVVENVPILGLYQIPAEGGGRIVLYG
DSNCLDDSHRQKDCFWLLDALLQYTSYGVTPPSLSHSGNRQRPPSGAGSVTPERMEGNHLHRYSK
VLEAHLGDPKPRPLPACPRLSWAKPQPLNETAPSNLWKHQKLLSIDLDKVVLPNFRSNRPQVRPL
SPGESGAWDI PGGIMPGRYNQEVGQTIPVFAFLGAMVLAFFVVQINKAKSRPKRRKPRVKRQPL
MQQVHPPKTPSV


FIG. 6

9




| | | | | | |
|----|-----|------------------|----|-----|-------------------|
| 1 | A12 | IKDFHVYFRESRDA | 49 | E12 | SATSRGVLVVAASGN |
| 2 | A11 | LEQAVNSATSRGVLV | 50 | E11 | SRGVLLVVAASGNNSGA |
| 3 | A10 | AQSVPWGISRQAPAA | 51 | E10 | VLVVAASGNSGAGS I |
| 4 | A9 | VPWGISRQAPAAHN | 52 | E9 | VAASGNSGAGSISYP |
| 5 | A8 | GISRVQAPAAHNRLG | 53 | E8 | SGNSGAGSISYPARY |
| 6 | A7 | RVQAPAAHNRLGTVK | 54 | E7 | SGAGSISYPARYANA |
| 7 | A6 | APAAHNRLGTVKAV | 55 | E6 | GSISYPARYANAMAV |
| 8 | A5 | AHNRLGTVKAVLDT | 56 | E5 | SYPARYANAMAVGAT |
| 9 | A4 | RGLTGSGVKAVALDT | 57 | E4 | ARYANAMAVGATDQN |
| 10 | A3 | TGSGVKAVALDTGIS | 58 | E3 | ANAMAVGATDQNNNR |
| 11 | A2 | GVKAVALDTGISTHP | 59 | E2 | MAVGATDQNNNRASF |
| 12 | A1 | VAVLDTGISTHPDLN | 60 | E1 | GATDQNNNRASFQY |
| 13 | B12 | LDTGISTHPDLNIRG | 61 | F12 | DQNNNRASFQYGAG |
| 14 | B11 | GISTHPDLNIRGGAS | 62 | F11 | NNRASFQYGAGLDI |
| 15 | B10 | THPDLNIRGGASFVP | 63 | F10 | ASFSQYGAGLDIVAP |
| 16 | B9 | DLNIRGGASFVPGEPE | 64 | F9 | SQYGAGLDIVAPGVN |
| 17 | B8 | IRGGASFVPGEPESTQ | 65 | F8 | GAGLDIVAPGVNVQS |
| 18 | B7 | GASFVPGEPESTQDG | 66 | F7 | LDIVAPGVNVQSTYP |
| 19 | B6 | FVPGEPESTQDGNGHG | 67 | F6 | VAPGVNVQSTYPGST |
| 20 | B5 | GEPSTQDGNGHGTHV | 68 | F5 | GVNVQSTYPGSTYAS |
| 21 | B4 | STQDGNGHGTHVAGT | 69 | F4 | VQSTYPGSTYASLNG |
| 22 | B3 | DGNHGTHVAGTIAA | 70 | F3 | TYPGSTYASLNGTSM |
| 23 | B2 | GHGTHVAGTIAALNN | 71 | F2 | GSTYASLNGTSMATP |
| 24 | B1 | THVAGTIAALNNSIG | 72 | F1 | YASLNGTSMATPHVA |
| 25 | C12 | AGTIAALNNSIGVLG | 73 | G12 | LNGTSMATPHVAGAA |
| 26 | C11 | IAALNNSIGVLGVAP | 74 | G11 | TSMATPHVAGAAALV |
| 27 | C10 | LNNSIGVLGVAPSAE | 75 | G10 | ATPHVAGAAALVKQK |
| 28 | C9 | SIGVLGVAPSAELYA | 76 | G9 | HVAGAAALVKQKNPS |
| 29 | C8 | VLGVAPSAELYAVKV | 77 | G8 | GAAALVKQKNPSWSN |
| 30 | C7 | VAPSAELYAVKVLGA | 78 | G7 | ALVKQKNPSWSNVQI |
| 31 | C6 | SAELYAVKVLGASGS | 79 | G6 | KQKNPSWSNVQIRNH |
| 32 | C5 | LYAVKVLGASGSGSV | 80 | G5 | NPSWSNVQIRNLK |
| 33 | C4 | VKVLGASGSGSVSSI | 81 | G4 | WSNVQIRNLKNTAT |
| 34 | C3 | LGASGSGSVSSIAQG | 82 | G3 | VQIRNLKNTATSLG |
| 35 | C2 | SGSGSVSSIAQGLEW | 83 | G2 | RNHLKNTATSLGSTN |
| 36 | C1 | GSVSSIAQGLEWAGN | 84 | G1 | LKNTATSLGSTNLYG |
| 37 | D12 | SSIAQGLEWAGNNGM | 85 | H12 | TATSLGSTNLYGSGL |
| 38 | D11 | AQGLEWAGNNGMHVA | 86 | H11 | SLGSTNLYGSGLVNA |
| 39 | D10 | LEWAGNNGMHVA | 87 | H10 | STNLYGSGLVNAEAA |
| 40 | D9 | AGNNGMHNANLSLGS | 88 | H9 | NLYGSGLVNAEATR |
| 41 | D8 | NGMHVANANLSLGS | | | |
| 42 | D7 | HVANANLSLGS | | | |
| 43 | D6 | NLSLGSPSPSATLEQ | | | |
| 44 | D5 | LGSPSPSATLEQAVN | | | |
| 45 | D4 | PSPSATLEQAVNSAT | | | |
| 46 | D3 | SATLEQAVNSATSRG | | | |
| 47 | D2 | LEQAVNSATSRGV | | | |
| 48 | D1 | AVNSATSRGVVAA | | | |

FIG. 7



| | | | | | |
|----|-----|------------------|----|-----|-----------------|
| 1 | A12 | IKDFHVYFRESRDA | 49 | E12 | KKIDVLNLSIGGPDF |
| 2 | A11 | DAELHIFRVFTNNQV | 50 | E11 | DVLNLSIGGPDFMDH |
| 3 | A10 | PLRRASLSLGSGFWH | 51 | E10 | NLSIGGPDFMDHPFV |
| 4 | A9 | RASLSLGSGFWHATG | 52 | E9 | IGGPDFMDHPFVDKV |
| 5 | A8 | LSLGSFHWATGRHS | 53 | E8 | PDFMDHPFVDKVWEL |
| 6 | A7 | GSGFWHATGRHSSRR | 54 | E7 | MDHPFVDKVWELTAN |
| 7 | A6 | FWHATGRHSSRRLLR | 55 | E6 | PFVDKVWELTANNVI |
| 8 | A5 | ATGRHSSRRLLRAIP | 56 | E5 | DKVWELTANNVIMVS |
| 9 | A4 | RHSSRRLLRAIPRQV | 57 | E4 | WELTANNVIMVSAIG |
| 10 | A3 | SRRLLRRAIPRQVAQT | 58 | E3 | TANNVIMVSAIGNDG |
| 11 | A2 | LLRAIPRQVAQTLQA | 59 | E2 | NVIMVSAIGNDGPLY |
| 12 | A1 | AIPRQVAQTLQADVL | 60 | E1 | MVSAIGNDGPLYGTJ |
| 13 | B12 | RQVAQTLQADVLWQM | 61 | F12 | AIGNDGPLYGTLNNP |
| 14 | B11 | AQTLQADVLWQMGT | 62 | F11 | NDGPLYGTLNNPADQ |
| 15 | B10 | LQADVLWQMGTGAN | 63 | F10 | PLYGTLNNPADQMDV |
| 16 | B9 | DVLWQMGTGANVRV | 64 | F9 | GTLNNPADQMDVI |
| 17 | B8 | WQMGTGANVRVAVF | 65 | F8 | NNPADQMDVIGVGGI |
| 18 | B7 | GYGANVRVAVFDTG | 66 | F7 | ADQMDVIGVGGIDFE |
| 19 | B6 | GANVRVAVFDTGLSE | 67 | F6 | MDVIGVGGIDFEDNI |
| 20 | B5 | VRVAVFDTGLSEKHP | 68 | F5 | IGVGGIDFEDNIARF |
| 21 | B4 | AVFDTGLSEKHPHFK | 69 | F4 | GGIDFEDNIARFSSR |
| 22 | B3 | DTGLSEKHPFKNVK | 70 | F3 | DFEDNIARFSSRGMT |
| 23 | B2 | LSEKHPFKNVKERT | 71 | F2 | DNIARFSSRGMTTWE |
| 24 | B1 | KHPFKNVKERTNWT | 72 | F1 | ARFSSRGMTTWE |
| 25 | C12 | HFKNVKERTNWTNER | 73 | G12 | SSRGMTTWE |
| 26 | C11 | NVKERTNWTNERLTD | 74 | G11 | PGGYGRMKPDI |
| 27 | C10 | ERTNWTNERLDDGL | 75 | G10 | PGGYGRMKPDI |
| 28 | C9 | NWTNERTLDDGLGHG | 76 | G9 | PGGYGRMKPDI |
| 29 | C8 | NERLDDGLGHGTFV | 77 | G8 | PGGYGRMKPDI |
| 30 | C7 | TLDDGLGHGTFVAGV | 78 | G7 | PGGYGRMKPDI |
| 31 | C6 | DGLGHGTFVAGVIAS | 79 | G6 | PGGYGRMKPDI |
| 32 | C5 | GHGTFVAGVIASMRE | 80 | G5 | PGGYGRMKPDI |
| 33 | C4 | TFVAGVIASMRECOQG | 81 | G4 | PGGYGRMKPDI |
| 34 | C3 | AGVIASMRECOGFAP | 82 | G3 | PGGYGRMKPDI |
| 35 | C2 | IASMRECQGFAPDAE | 83 | G2 | PGGYGRMKPDI |
| 36 | C1 | MRECQGFAPDAELHI | 84 | G1 | PGGYGRMKPDI |
| 37 | D12 | CQGFAPDAELHI | 85 | H12 | PGGYGRMKPDI |
| 38 | D11 | FAPDAELHI | 86 | H11 | PGGYGRMKPDI |
| 39 | D10 | DAELHI | 87 | H10 | PGGYGRMKPDI |
| 40 | D9 | FRVFTNNQVSYT | 88 | H9 | PGGYGRMKPDI |
| 41 | D8 | FRVFTNNQVSYT | 89 | H8 | PGGYGRMKPDI |
| 42 | D7 | FTNNQVSYT | 90 | H7 | PGGYGRMKPDI |
| 43 | D6 | NQVSYT | 91 | H6 | PGGYGRMKPDI |
| 44 | D5 | SYT | 92 | H5 | PGGYGRMKPDI |
| 45 | D4 | WFLDAFNYAILKKI | 93 | H4 | PGGYGRMKPDI |
| 46 | D3 | LDAFNYAILKKI | 94 | H3 | PGGYGRMKPDI |
| 47 | D2 | FNYAILKKI | 95 | H2 | PGGYGRMKPDI |
| 48 | D1 | AILKKI | 96 | H1 | PGGYGRMKPDI |

FIG. 8A



| | | |
|-----|-----|------------------|
| 97 | I12 | IKDFHVYFRESRDAG |
| 98 | I11 | DAELHI FRVFTNNQV |
| 99 | I10 | KQALIASARRLPGVN |
| 100 | I9 | LIASARRLPGVNMFE |
| 101 | I8 | SARRLPGVNMFEQGH |
| 102 | I7 | RLPGVNMFEQGHGKL |
| 103 | I6 | GVNMFEQGHGKLDLL |
| 104 | I5 | MFEQGHGKLDLLRAY |
| 105 | I4 | QGHGKLDLLRAYQIL |
| 106 | I3 | GKLDLLRAYQILNSY |
| 107 | I2 | DLLRAYQILNSYKPQ |
| 108 | I1 | RAYQILNSYKPQASL |
| 109 | J12 | QILNSYKPQASLSPS |
| 110 | J11 | NSYKPQASLSPSYID |
| 111 | J10 | KPQASLSPSYIDLTE |
| 112 | J9 | ASLSPSYIDLTECPY |
| 113 | J8 | SPSYIDLTECPYMW |
| 114 | J7 | YIDLTECPYMWPYCS |
| 115 | J6 | LTECPYMWPYCSQPI |
| 116 | J5 | CPYMWPYCSQPIYYG |

FIG. 8B

